semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Hypothyroidism Subjects will be between the ages of 18 to 65 and will have been on levothyroxine for primary hypothyroidism for at least 6 months Department of Defense beneficiaries living within 60 miles of Besthesda, MD  Subjects will be excluded if they have the following problems: pregnancy, plan for pregnancy in the next 12 months, cardiac disease, especially coronary artery disease, chronic obstructive lung disease, malabsorption disorder, gastrointestinal surgeries, significant renal or liver dysfunction, seizure disorders, thyroid and non-thyroid active cancers, uncontrolled psychosis, psychotropic medication use, steroid use, amiodarone, chemotherapy for cancer, iron supplement more than 325mg per day, carafate/ proton pump inhibitor use, cholestyramine use, and those with recent orders who are expected to move out of the geographic area, age less than 18 years old or older than 65 years old. Patients scheduled for deployment will be excluded Subjects with subclinical hypothyroidism will be excluded. If we patients with subclinical hypothyroidism, it will be difficult to assess the outcomes. This is because only a very small percentage of patients with subclinical hypothyroidism benefit from thyroid hormone therapy and therefore, a cross-over study as done in this project will not show a difference between the therapies Females of child-bearing age will be screened with initial assessment for pregnancy as part of standard of care (eg history of amnenorrhea and/or positive pregnancy testing via hCG). There is no experience in using desiccated thyroid extract in pregnant women and there is no published paper in this area. Desiccated thyroid extract is rated Category-A drug in pregnancy which means there are no known risks to the fetus
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 6.0-18.0,  Autoimmune Thyroiditis Newly diagnosed AIT Age >6 years <18 years Iodine sufficient region  Children on antioxidants or antithyroid drugs Cardiac, renal and hepatic disease Children with other autoimmune and collagen diseases
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hashimoto's Disease Patients referred due to typical symptoms, believed to be related to Hashimoto´s disease, but not relieved by thyroxin substitution. Optimal thyroid substitution treatment is already provided. 2. Anti-TPO>1000 3. Hypothyroidism with a need for thyroxin supplementation 4. Written informed consent by the patient information particularly emphasising and quantifying the risk of complications (e.g. recurrent laryngeal nerve palsy). The patient should be informed by a medical endocrinologist as well as a surgeon  Patients <18 years of age. 2. Pregnancy. 3. Unable to comprehend information adequately to give informed consent. 4. General anaesthesiological contraindications. 5. An unexpected finding of cancer in the surgical group is not a reason for per se, but this group should be analyzed separately. It is expected that any different loading in Quality of life would bias the medically treated group
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Drug Interactions Healthy male subjects between the ages of 18 (inclusive) and 45 years (inclusive) at the first screening visit Body mass index (BMI) between 18.5 (inclusive) to 30.0 kg / m² (inclusive) with body weight ≥ 65kg Normal thyroid function indicated by thyroid examination to total and free T3 (Triiodothyronine) , T4 (total and free Thyroxine, levothyroxine), TSH (Thyroid stimulating hormone), anti-TSH-receptor (anti-TSHR) antibody, anti-thyroperoxidase (anti-TPO) antibody, anti-thyroglobulin antibody (anti-ATA) as well as thyroid ultrasound  History of clinically significant metabolic, renal, hepatic, or central nervous system disorder such as seizure, psychosis and sleep disorders History of cardiovascular diseases including arrhythmia, hypertension, ischemia, etc Known or suspected cardiovascular disease including potential risk of atrioventricular (AV) block, arrhythmia, etc. with or without a formal cardiologist consultation Subjects who had received iodine containing contrast medium within 2 months before first study drug administration Use of systemic or topical medicines or substances which might affect the study drug(s) must be avoided
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Preeclampsia Women who delievered at the Department of Obstetrics at Randers Regional Hospital 1998-2008  Current pregnancy or breastfeeding
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 8.0-21.0,  Drug Distribution Children 8-21 years of age 2. LDL cholesterol >130mg/dl (>95% percentile) 3. Successfully genotyped for SLCO1B1 4. Willing to sign the assent/permission/consent form  Underlying structural heart disease including congenital heart disease or acquired heart disease. 2. History or laboratory evidence of an underlying intestinal, metabolic, autoimmune, or renal disease that could alter the disposition of simvastatin or pravastatin. 3. Underlying pathology of the gastrointestinal tract or recent surgery which would be expected to alter the rate and/or extent of drug absorption 4. Evidence of previous hypersensitivity to statin medications 5. Unwillingness or inability to have screening labs drawn 6. Refusal to participate in the study 7. Unwillingness or inability to participate in an overnight fast 8. Subjects taking drugs with interactions with statins (CYP3A4 inducers/inhibitors, OATP1B1 inducers/inhibitors) 9. Inability to swallow a tablet drug 10. For females, a positive urine beta-human chorionic gonadotropin pregnancy test result 11. Evidence of hepatic abnormality as determined by values > 3 times the age-specific upper limit of normal for AST, ALT, total and conjugated bilirubin, serum albumin, Alkaline Phosphatase, and GGT. 12. Abnormal red blood cell morphology and/or a hemoglobin less than 9 gm/dl
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  Pediatric Population on Second Generation Antipsychotics Children aged 10 to 17 years currently treated with one or more antipsychotics as determined by a physician 2. No changes in antipsychotic dosage for the past 6 weeks  Guardian or child unwilling or unable to participate. 2. A diagnosis of diabetes or dyslipidemia prior to starting an antipsychotic. 3. Abuse or dependence diagnoses
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Graves' Disease A first time diagnosis of Graves' hyperthyroidism within the last three months, confirmed by TSH below 0.01 IU/L, and T3 or T4 levels above the reference interval necessitating ATD therapy Positive TRAb Speak and read Danish Written informed consent  Previously diagnosed hyperthyroidism ATD treatment initiated more than 3 months prior to Planned ablative therapy (radioactive iodine or thyroid surgery) Intake of more than 10 µg D-vitamin/day that the participant wishes to continue Chronic granulomatous illness Persistent hypercalcemia (plasma calcium > 1.40 mmol/L) Reduced kidney function (eGFR < 45 ml/min) Treatment with immunomodulatory drugs Active malignant disease Alcohol or drug abuse
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Thyroid Eye Disease Mild TED of less than 18 months duration (as recorded by the patient). 2. No active state (Clinical activity score of less than 3). 3. No previous specific therapy for TED, except for local measures (artificial tear, head elevation, low salt diet). 4. Euthyroidism as a result of remission after a course of antithyroid drug (ATD) therapy, or euthyroidism for at least 2 months since commencing ATD or after thyroidectomy, or euthyroidism for at least 6 months after radioiodine therapy. Hypothyroid patients after thyroidectomy or radioiodine were replaced with levothyroxine. Euthyroidism was defined as normal serum free thyroxine, total or free triiodothyronine concentrations, and thyrotropin (TSH) levels below 4 mU/Liter Patients were kept euthyroid for the whole duration of the study. 5. Age 18-70 years  TED severity of more than mild TED. 2. Pregnancy 3. Drug and/or alcohol abuse 4. Severe concomitant illness 5. Inability to comply with the study protocol 6. No informed consent 7. Use of selenium or vitamin/minerals-containing preparations in the last 3 months. 8. Developing more severe TED in the course of the trial so that requires steroid treatment
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 70.0-999.0,  Subclinical Hypothyroidism men and women aged 70 and older 2. TSH between 4.5 and 19.9 mU/L as an outpatient 3. ability to provide informed consent  Laboratory Tests: 1. TSH <4.5 mU/L or >20 mU/L on repeat testing at least four weeks later or free T4 level outside the reference range 2. thyroid peroxidase (TPO) antibody positive 3. abnormal liver function tests (LFTs >3 x upper limit of normal) 4. hemoglobin <11 g/dL Surgeries or Procedures: 1. thyroid surgery 2. pituitary surgery 3. bariatric surgery 4. bowel resection involving the jejunum and upper ileum 5. radioactive iodine therapy 6. radiation treatments to head or neck Medical Conditions: 1. diagnosis of pituitary disease 2. diagnosis of amyloidosis, sarcoidosis, hemochromatosis 3. diagnosis of adrenal insufficiency 4. obesity with BMI > 35 mg/kg2 5. history of stroke 6. chronic or ongoing angina, Class II or higher congestive heart failure, or uncontrolled hypertension with current blood pressure greater than 160/100 7. diabetes mellitus with hemoglobin A1C level greater than 8.0% in the past six months 8. celiac sprue, Crohn's disease, ulcerative colitis, Zollinger-Ellison syndrome 9. renal insufficiency with calculated glomerular filtration rate <45 cc/min 10. cognitive impairment with Mini Mental State Exam[30] <24/30 11. history of any seizures 12. unstable medical or psychological condition in the judgment of the principal investigator Medications: 1. thyroid hormone preparations 2. antithyroid drugs 3. medications that interfere with the absorption or metabolism of thyroid hormone 4. medications that interfere with the TRH stimulation test 5. proton pump inhibitors
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pregnancy Pregnant females exposed to lomitapide at any time within 30 days prior to first day of the LMP or during pregnancy  Patients who are unable or unwilling to provide written informed consent or assent are not eligible to participate in the PER
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Inherited Cardiac Arrythmias Long QT Syndrome (LQTS) Brugada Syndrome (BrS) Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Early Repolarization Syndrome (ERS) Arrhythmogenic Cardiomyopathy (AC, ARVD/C) Hypertrophic Cardiomyopathy (HCM) Dilated Cardiomyopathy (DCM) Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) Normal Control Subjects All patients and family members 18 years of age or older with inherited cardiac arrhythmias including LQTS, Brugada Syndrome (BrS), cathecholaminergic polymorphic ventricular tachycardia (CPVT) or early repolarization syndrome (ERS) are eligible for enrollment All enrolled patients will have undergone clinically indicated genetic testing  Age <18 years >85 years pregnant women life-limiting co-morbidities immunocompromise
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 12.0-18.0,  Vitamin D Deficiency Obese subjects BMI at or above the 95th percentile for children of the same age and sex. Only obese subjects will be selected given that they are the highest risk group of developing insulin resistance and Type II Diabetes and therefore with be most likely to demonstrate glucose pertubation. 2. Pubertal: Testicular volume ≥ 6 ml Prader (M) and Tanner III breast development or greater (F) 3. 12 years regardless of gender, race or economic circumstance 4. Pre diabetes/high risk of diabetes using of HbA1C between 5.7 4% as defined by the American Diabetes Association (ADA) 5. 25-OH vitamin D level less than 20 ng/ml (50 nmol/liter) 6. Subjects must be willing to comply with study protocol requirements  Treatment on medication known to effect vitamin D, calcium and glucose metabolism, such as glucocorticoids, thiazolidinediones, metformin, anticonvulsants metabolized through cytochrome P-450 (phenytoin, carbamazepine, phenobarbital, sodium valproate). 2. Subjects will be excluded from the study if they have taken any form of vitamin D supplementation greater than 400 IU daily in the preceding 3 months. 3. Significant major organ system illness 4. History of nephrolithiasis or hypercalcemia 5. Females who are pregnant 6. Significant psychiatric illness: schizophrenia, bipolar disorder, active substance abuse, and uncontrolled major depression. 7. Attendance at tanning salon
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Health Problems in Pregnancy English speaking female patients presenting for medical care at the Regional One Health perinatal clinics or Regional One Health Labor and Delivery Dept. will be asked to participate in the study  Those not meeting the above criteria
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Leishmaniasis Did the subject give consent to collect data from her or her physician? 2. Was the subject treated for leishmaniasis with miltefosine? 3. Does the subject weigh more than 75 kg?  [none]
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 16.0-35.0,  Primary Dysmenorrhoea Women had regular menstrual cycles lasted 21 to 35 days, with menstruation lasting 3 to 7 days; 2. Women had to be in good health and taking no medications including calcium, magnesium, vitamin D and oral contraceptives. 3. Women had not a previous history of gynaecological disease, and a normal pelvic examination were eligible  Previous and current use of intrauterine contraceptive devices within the 6 months to enrollment was not permitted
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Abdominal Aortic Aneurysms Diagnosed abdominal aortic aneurysm with indication for endovascular repair. 2. Intention to electively implant the Aorfix™ Stent Graft System  Does not comply with the indications for Aorfix™ in the Instructions for Use (IFU). 2. Unwillingness or inability to comply with the recommended follow-up assessments according to the standards of care at the investigative site. 3. Unwillingness or inability to provide informed consent to both the Registry and the EVAR procedure. 4. Patients in whom Aorfix™ is being placed as a secondary procedure to a previous surgical or endovascular treatment of an AAA other than with another Aorfix™ graft